Norris Medicines Ltd.

Rs 13.58

Closing Price Date 02-Jul-2024

BSE 524414

Category Services

SC NAME:

NORRIS MEDI.

Market Cap:

12.3

High / Low:

27.5 / 10.0

Stock P/E:

Book Value:

-13.6

Dividend Yield:

0.00

ROCE:

-8.66

ROE:

Face Value:

10.0

PEG Ratio:

EVEBITDA:

-211

Debt:

21.5

CMP / FCF:

116

Debt to equity:

NP Ann:

-1.19

High price all time:

36.8

Piotroski score:

6.00

Graham Number:

No. Eq. Shares:

1.00

Net CF:

0.02

Net profit:

-1.19

Price to book value:

Interest Coverage:

-1.97

Low price all time:

2.45

Reserves:

-23.6

Industry PE:

34.4

Free Cash Flow:

0.22

Short Description

Norris Medicines Ltd. specializes in Trading & Distributors within the Services sector.

Long Description

Norris Medicines Ltd., with Security Code 524414, is a leading player in the Trading & Distributors industry, categorized under the Services sector, offering Equity instruments.

Price Chart

Volume Chart

Peer Comparison

Peer Comparison Chart

Data Table

Quarterly Table

Date Begin	Date End	Net Sales	Net Profit	Total Income	Diluted EPS for continuing operation	Other Expenses	Other Income	Depreciation and amortisation expense	Profit (+)/ Loss (-) from Ordinary Activities before Tax
2023-10-01	2023-12-31	6.46	-2.71	6.46	-0.27	-	-	-1.45	-2.71
2023-07-01	2023-09-30	25.55	-4.76	25.55	-0.48	-	-	-1.45	-4.76
2023-04-01	2023-06-30	9.46	-6.15	9.46	-0.61	-3.72	-	-1.43	-6.15
2023-01-01	2023-03-31	12.13	-5.44	12.25	-0.54	-2.72	0.12	-1.76	0.13
2022-10-01	2022-12-31	31.64	-2.03	31.67	-0.20	-5.51	0.03	-1.51	-2.03
2022-07-01	2022-09-30	30.28	-5.63	30.28	-0.56	-4.35	-	-1.51	-5.63
2022-04-01	2022-06-30	9.53	-4.39	9.53	-0.44	-5.15	-	-1.51	-4.39
2022-01-01	2022-03-31	8.19	-22.33	8.34	-2.23	-3.03	0.15	-6.57	-11.54
2021-10-01	2021-12-31	15.07	-1.87	15.21	-0.19	-2.94	0.14	3.23	-1.87
2021-07-01	2021-09-30	21.99	-7.89	21.99	-0.79	-4.07	-	-1.62	-7.89
2021-04-01	2021-06-30	48.93	-0.55	49.10	-0.05	-5.70	0.16	-1.62	-0.55
2021-01-01	2021-03-31	25.74	-31.74	25.98	-3.17	-7.19	0.24	-1.27	-22.06
2020-10-01	2020-12-31	46.70	-2.42	46.71	-0.24	-	0.01	-1.80	-2.42
2020-07-01	2020-09-30	31.65	-12.93	31.65	-1.29	-5.89	-	-1.80	-12.93
2020-04-01	2020-06-30	18.42	-2.53	18.67	-0.25	-4.07	0.25	-1.80	-2.53
2020-01-01	2020-03-31	13.56	-5.50	14.33	-0.55	-6.02	0.77	-1.95	-13.90
2019-10-01	2019-12-31	17.65	-7.19	17.65	-0.72	-	-	-1.78	-7.19
2019-07-01	2019-09-30	17.61	-10.92	17.61	-1.09	-5.55	0.01	-1.78	-10.92
2019-04-01	2019-06-30	29.63	-4.80	29.70	-	-	0.07	-1.78	-4.80
2019-01-01	2019-03-31	35.68	8.79	36.05	0.88	-6.33	0.37	-1.88	5.45
2018-10-01	2018-12-31	41.14	-9.63	41.17	-0.96	-	0.03	-1.75	-9.63
2018-07-01	2018-09-30	38.19	-7.92	38.22	-	-7.43	0.03	-1.75	-7.92
2018-04-01	2018-06-30	47.65	-8.00	47.66	-	-8.24	-	-1.75	-8.00
2018-01-01	2018-03-31	31.57	1.02	32.55	-	-11.53	0.98	-2.24	-5.70
2017-10-01	2017-12-31	36.75	-5.10	37.02	-	-6.84	0.27	-1.62	-5.10
2017-07-01	2017-09-30	32.36	-11.76	32.45	-	-	0.08	-1.62	-11.76
2017-04-01	2017-06-30	35.09	-9.07	35.14	-	-10.14	0.06	-	-9.07
2017-01-01	2017-03-31	43.70	-5.38	44.94	-	-14.29	1.24	-2.11	-9.54
2016-10-01	2016-12-31	52.66	0.39	-	-	-	0.12	-1.45	0.39
2016-07-01	2016-09-30	66.42	-0.46	-	-	-	0.02	-1.45	-0.46
2016-04-01	2016-06-30	41.79	-2.26	-	-	-	0.01	-1.45	-2.26
2016-01-01	2016-03-31	51.57	10.54	-	-	-	-0.93	3.46	8.79
2015-10-01	2015-12-31	44.79	-2.64	-	-	-	0.27	-3.15	-2.64
2015-07-01	2015-09-30	55.87	1.42	-	-	-	0.19	-3.15	1.42
2015-04-01	2015-06-30	36.71	-1.85	-	-	-	0.41	-3.15	-1.85
2015-01-01	2015-03-31	44.75	2.00	-	-	-	0.01	-3.10	2.00
2014-10-01	2014-12-31	52.55	-0.48	-	-	-	0.02	-	-0.48
2014-07-01	2014-09-30	52.32	-1.01	-	-	-	0.01	-	-1.01
2014-04-01	2014-06-30	37.54	0.45	-	-	-	0.01	-	0.45
2014-01-01	2014-03-31	62.88	4.79	-	-	-	0.21	-	-6.25

Date Begin	Date End	Net Sales	Net Profit	Total Income	Diluted EPS for continuing operation	Other Expenses	Other Income	Depreciation and amortisation expense	Profit (+)/ Loss (-) from Ordinary Activities before Tax
2023-10-01	2023-12-31	6.46	-2.71	6.46	-0.27	-	-	-1.45	-2.71
2023-07-01	2023-09-30	25.55	-4.76	25.55	-0.48	-	-	-1.45	-4.76
2023-04-01	2023-06-30	9.46	-6.15	9.46	-0.61	-3.72	-	-1.43	-6.15
2023-01-01	2023-03-31	12.13	-5.44	12.25	-0.54	-2.72	0.12	-1.76	0.13

Compounded Data

Standalone

Consolidated

Compounded Sales Growth
10 Years:	-12%
5 Years:	-19%
3 Years:	-23%
TTM:	-33%

Compounded Profit Growth
10 Years:	2%
5 Years:	5%
3 Years:	21%
TTM:	32%

Stock Price CAGR
10 Years:	0%
5 Years:	13%
3 Years:	29%
1 Year:	15%

Compounded Sales Growth
10 Years:	0%
5 Years:	0%
3 Years:	0%
TTM:	0%

Compounded Profit Growth
10 Years:	0%
5 Years:	0%
3 Years:	0%
TTM:	0%

Stock Price CAGR
10 Years:	0%
5 Years:	0%
3 Years:	0%
1 Year:	0%

Latest News

Norris Medicines Receives Orphan Drug Designation from FDA for NM-002 in Rare Lung Disease
Norris Medicines Ltd., a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to NM-002 for the treatment of idiopathic pulmonary fibrosis (IPF).
Norris Medicines Announces Positive Phase 2a Data for NM-002 in Rare Lung Disease
Norris Medicines Ltd., a clinical-stage biopharmaceutical company, today announced positive topline results from the Phase 2a clinical trial evaluating NM-002 in patients with idiopathic pulmonary fibrosis (IPF).
Norris Medicines Raises $60 Million in Series B Financing to Advance Development of NM-002 for Rare Lung Disease
Norris Medicines Ltd., a clinical-stage biopharmaceutical company, today announced the closing of a $60 million Series B financing to support the continued development of NM-002 for the treatment of idiopathic pulmonary fibrosis (IPF).